AWM
FATE icon

AE Wealth Management’s Fate Therapeutics FATE Stock Holding History

AE Wealth Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,885
Closed -$480K – 1991
2023
Q2 		$480K Buy
+100,885
New +$557K ﹤0.01% 1415
2023
Q1 		– Sell
-51,331
Closed -$518K – 1912
2022
Q4 		$518K Buy
+51,331
New +$964K ﹤0.01% 1301
2020
Q4 		– Sell
-15,536
Closed -$621K – 1377
2020
Q3 		$621K Buy
+15,536
New +$542K 0.01% 799

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AE Wealth Management's FATE Position: Q3 2023 in Review

AE Wealth Management sold out of Fate Therapeutics (FATE) in Q3 2023, closing a stake of 100,885 shares — an estimated $480K sold.

AE Wealth Management first reported a position in FATE in Q3 2020 and held it in 3 quarters. The position peaked at $621K in Q3 2020. 170 funds tracked by Wall St. Rank hold FATE as of Q3 2023.

  • AE Wealth Management reported no remaining Fate Therapeutics position as of Q3 2023 after selling out during the quarter.
  • AE Wealth Management sold 100,885 Fate Therapeutics shares in Q3 2023, an estimated $480K.
  • AE Wealth Management first reported a position in Fate Therapeutics in Q3 2020 and held it in 3 quarters.
  • AE Wealth Management's Fate Therapeutics position peaked at $621K in Q3 2020.
  • 170 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2023.

Based on AE Wealth Management's 13F filing for Q3 2023, filed 11 Oct 2023.